drugset

drugset / Trial / NCT00078000

A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

NCT00078000 ↗

Phase 2 Completed 64 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.

Timeline

Start: 2004-03
Primary completion: —
Completion: 2005-11

Publications

Keyvanjah K, DePrimo SE, Harmon CS, Huang X, Kern KA, Carley W. Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. J Transl Med. 2012 Aug 16;10:165. doi: 10.1186/1479-5876-10-165.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	50 mg	—

Indications